Abstract
The University of Texas MD Anderson Cancer Center will purchase Bellicum Pharmaceuticals’ approximately 5,500 m2 cell therapy facility in Houston, including manufacturing, office, and lab space, for $15 million. MD Anderson will operate the facility both for its own internal programs and to manufacture Bellicum’s GoCAR and other cell therapies for clinical trials and potentially early commercial supply. Bellicum says the deal will allow it to reduce expenses while keeping access to product supply.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
